Willow Company Overview and Business Model

What Willow Actually Does

Willow connects women seeking GLP-1 receptor agonist therapy with licensed prescribers through an asynchronous telehealth model. Patients complete an intake questionnaire, upload relevant medical history, and receive a prescriber review. No in-person visit is required. The platform then ships medication directly or routes prescriptions to a partner pharmacy.

This model mirrors other direct-to-consumer telehealth platforms such as Ro, Hims & Hers, and Calibrate. What distinguishes Willow is its explicit focus on women. The clinical rationale is sound: women represent approximately 70% of GLP-1 prescriptions according to pharmacy claims data analyzed by IQVIA and reported through JAMA, and sex-specific metabolic differences affect both efficacy and side-effect profiles. A 2023 subgroup analysis of the STEP trials found that women on semaglutide 2.4 mg experienced 15.8% mean body weight reduction at 68 weeks, compared with 14.2% in men [1]. Whether Willow's platform design actually leverages these differences in its clinical protocols remains unverified, as the company has not published its treatment algorithms.

The subscription includes access to a care team, but the depth of ongoing support varies. Some users report frequent check-ins. Others describe a largely automated experience after the initial prescription. This inconsistency is a pattern across the cash-pay telehealth sector, not unique to Willow.

Business Model: How Willow Makes Money

Willow generates revenue through two streams: a monthly platform fee and a medication margin. The platform fee covers the consultation, messaging access to a prescriber, and periodic check-ins. Medication is billed separately, with pricing that varies based on whether the patient receives a brand-name GLP-1 or a compounded formulation.

Brand-name semaglutide (Wegovy) carries a list price of approximately $1,349 per month without insurance, per GoodRx pricing data and FDA label information. Willow's pricing for brand-name GLP-1s reflects this cost with a modest markup for the service layer. Compounded semaglutide, when offered, drops the medication cost significantly. The FDA has stated that compounded drugs are not FDA-approved and do not undergo the same review process, a distinction Willow's marketing does not always make clear.

The cash-pay-only model eliminates insurance friction, which is a genuine barrier. A 2024 KFF analysis found that fewer than 25% of large employer plans covered GLP-1s for obesity as of early 2024. For women without coverage, platforms like Willow become one of few accessible pathways. But bypassing insurance also means bypassing the prior-authorization process that, while burdensome, does serve as a clinical checkpoint. The American Association of Clinical Endocrinology (AACE) guidelines recommend that GLP-1 prescribing for obesity include baseline HbA1c, lipid panel, renal function, and a structured assessment of cardiovascular risk. Whether every Willow consultation includes these components is unclear from publicly available information.

Is Willow Legit?

Willow operates within the legal framework established by state telemedicine laws. It uses licensed prescribers. It dispenses FDA-approved medications (when prescribing brand-name products). These are necessary conditions for legitimacy, not sufficient ones.

Legitimacy in the GLP-1 telehealth space should be measured against clinical standards. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity specifies that anti-obesity medications should be prescribed within a framework that includes dietary counseling, physical activity guidance, behavioral support, and regular metabolic monitoring. A platform that prescribes a GLP-1 after a five-minute asynchronous review with no lab work and no follow-up plan falls short of this standard, regardless of whether it holds valid medical licenses.

Willow's website references physician oversight. The question is density. How many patients does each prescriber manage? What is the average time spent per consultation? These metrics are not disclosed. For comparison, Calibrate publicly reports a 1:100 prescriber-to-patient ratio and structured 12-month protocols. Willow has not made equivalent disclosures.

The FTC has increased enforcement against telehealth companies making unsupported weight-loss claims, particularly those selling compounded peptides. Willow has not been the subject of any public enforcement action, but consumers should verify that any telehealth platform they use is transparent about prescriber credentials, medication sourcing, and refund policies.

What Does Willow Prescribe?

Willow's medication menu centers on GLP-1 receptor agonists and dual GIP/GLP-1 agonists. Based on publicly available information and user reports, the primary options include:

Semaglutide (brand names Wegovy and Ozempic). Wegovy is FDA-approved for chronic weight management in adults with BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity. In the STEP-1 trial (N=1,961), participants on semaglutide 2.4 mg achieved 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [2]. Ozempic is approved for type 2 diabetes but is frequently prescribed off-label for weight management.

Tirzepatide (brand names Zepbound and Mounjaro). Zepbound received FDA approval for obesity in November 2023. The SURMOUNT-1 trial (N=2,539) demonstrated 20.9% mean weight loss at 72 weeks with the 15 mg dose, the largest reduction seen in any Phase III obesity medication trial to date [3].

Compounded formulations. When brand-name supply is constrained, Willow has offered compounded semaglutide. The FDA's updated guidance on compounded semaglutide notes that compounded versions may differ in salt form, concentration, or sterility assurance from FDA-approved products. The agency removed semaglutide from its drug shortage list in early 2025, which affects the legal basis for 503A pharmacy compounding of this molecule.

Some user reports indicate that Willow also prescribes adjunctive medications such as metformin, bupropion/naltrexone (Contrave), and oral progesterone in the context of women's metabolic health. Metformin has shown modest weight-loss effects of 2 to 3% in the Diabetes Prevention Program (DPP), and its off-label use in PCOS and insulin resistance is supported by AACE guidelines [4].

Willow vs. Alternatives

The direct-to-consumer GLP-1 telehealth market includes at least a dozen active platforms. A fair comparison requires looking at clinical rigor, pricing transparency, medication options, and follow-up protocols.

Willow vs. Calibrate. Calibrate positions itself as a metabolic health company with a structured 12-month program. It requires baseline labs, pairs patients with a dedicated coach, and follows a defined titration protocol. Calibrate's pricing is higher (approximately $1,500 per year for the program fee, medication separate), but it publishes outcomes data: 15% average body weight loss at one year per its 2023 cohort report. Willow has not published equivalent data.

Willow vs. Ro (Body Program). Ro offers GLP-1 prescriptions through its Body Program at competitive cash-pay pricing. Ro has the advantage of an integrated pharmacy (Ro Pharmacy) and a larger prescriber network. Ro requires an initial video consultation in most states, which arguably provides a higher clinical touchpoint than asynchronous-only models.

Willow vs. Hims & Hers. The Hers platform, the women's vertical of Hims & Hers, offers compounded semaglutide at lower price points (as low as $199/month during promotional periods). However, the FDA's position on compounded semaglutide has created regulatory uncertainty for platforms heavily reliant on compounded supply. Both Willow and Hers face this risk.

A 2024 cross-sectional analysis published in Annals of Internal Medicine found that only 40% of telehealth weight-management platforms required baseline laboratory work before prescribing GLP-1s, and fewer than 25% provided structured dietary or behavioral support [5]. This finding suggests that most platforms, not just Willow, fall below guideline-recommended standards.

Women-Specific GLP-1 Considerations

Willow's focus on women raises a clinically relevant question: does sex matter in GLP-1 prescribing? The short answer is yes, in several measurable ways.

Women experience higher rates of GLP-1-related nausea. A pooled analysis of the STEP trial program reported nausea in 44.2% of women versus 35.7% of men on semaglutide 2.4 mg [2]. Slower gastric emptying at baseline, hormonal fluctuations across the menstrual cycle, and body composition differences all contribute. A women-focused platform could, in theory, tailor titration schedules and anti-nausea protocols to account for these differences. Whether Willow does this in practice is not documented in its public materials.

Reproductive considerations also matter. The Wegovy prescribing label recommends discontinuing semaglutide at least two months before a planned pregnancy based on animal reproductive toxicity data [6]. For women of reproductive age, this requires active contraception counseling and pregnancy screening as part of the prescribing workflow. The ACOG Committee Opinion on obesity pharmacotherapy supports this approach, recommending that clinicians discuss contraception plans before initiating any anti-obesity medication in premenopausal women [7].

Bone density is another sex-specific concern during rapid weight loss. Women lose approximately 1 to 2% of bone mineral density per 10% of body weight lost, according to data from the Fracture Intervention Trial and related analyses [8]. The STEP-4 extension trial did not report sex-stratified bone density outcomes, a gap in the evidence base. Platforms targeting women should, at minimum, screen for osteoporosis risk factors and consider DEXA scanning in high-risk patients. There is no indication that Willow's protocols include this.

Cost Structure and Value Assessment

Willow's pricing follows the standard cash-pay telehealth model. The platform fee ranges from $49 to $99 per month depending on the plan tier. Medication cost is separate and varies dramatically:

Compounded semaglutide through Willow has been reported at $299 to $399 per month. Brand-name Wegovy without insurance runs $1,349 per month at list price. Tirzepatide (Zepbound) lists at approximately $1,060 per month per the FDA-approved labeling.

Manufacturer savings programs can reduce brand-name costs substantially. Novo Nordisk's WeGoTogether savings program and Eli Lilly's savings card for Zepbound can bring out-of-pocket costs to $500 or less for eligible patients. These programs are available regardless of which platform prescribes the medication.

The value question is whether Willow's platform fee buys enough clinical support to justify the cost beyond a simple prescription. A single visit with a board-certified obesity medicine physician typically costs $200 to $350 and includes a comprehensive metabolic workup, individualized treatment planning, and referral coordination. For patients who can access in-person obesity medicine, this may represent better value than a monthly subscription to an asynchronous platform.

For women in areas with limited access to obesity medicine specialists (the ABOM directory lists fewer than 7,000 board-certified obesity medicine physicians in the United States), telehealth platforms like Willow provide access that would not otherwise exist. Access versus quality is the central tension. Both matter.

Red Flags and Green Flags

Green flags. Willow uses licensed prescribers. It offers FDA-approved brand-name medications. Its focus on women aligns with real clinical differences in GLP-1 response and side-effect profiles. The platform does not appear to make overtly false efficacy claims.

Red flags. No published clinical outcomes data. No disclosed prescriber-to-patient ratios. Inconsistent lab requirements across states. Heavy reliance on compounded medications with uncertain regulatory status. Limited transparency about refund policies and medication-switch protocols. No published information about behavioral or dietary support components.

The CDC's guidance on telehealth quality emphasizes that virtual care should meet the same clinical standards as in-person care, including documentation, follow-up, and continuity. Patients evaluating Willow should ask their assigned prescriber directly: what labs do you require, how often will we check in, what happens if I experience side effects, and what is the plan if I want to stop the medication?

GLP-1 discontinuation leads to weight regain of approximately two-thirds of lost weight within one year, per the STEP-1 extension data published in Diabetes, Obesity and Metabolism [9]. Any prescribing platform, Willow included, should have a clear protocol for medication discontinuation, dose tapering, and transition to maintenance strategies. Ask about this before enrolling.